Latest News Senhwa Biosciences Presents Clinical Data Abstract on Pidnarulex at 2024 ESMO Congress. Sep 09 2024 Latest News Senhwa Biosciences receives US FDA Study May Proceed letter for the Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors. Aug 07 2024 Latest News Senhwa Biosciences Clinical Data Abstract of Pidnarulex Accepted for Presentation at 2024 ESMO Congress. Jul 12 2024 Media Coverage AACR 2024 Annual Meeting-Visit Senhwa Biosciences Exhibit Booth Apr 03 2024 Media Coverage Senhwa Biosciences Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19 Nov 09 2023 Media Coverage Senhwa Biosciences Announces IND Submission to US FDA for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia (CAP) Associated with Viral Infection Oct 19 2023 Publications Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study Sep 24 2022 Publications Protein kinase CK2: a potential therapeutic target for diverse human diseases Jul 20 2021 Publications Integrating Proteomics for Facilitating Drug Identification and Repurposing During an Emerging Virus Pandemic Dec 17 2020